ArticleAnnals of surgical oncology2026
Anatomic-Biologic Borderline Resectability Criteria Improve Recurrence Risk Stratification in Perihilar Cholangiocarcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorderline resectability in perihilar cholangiocarcinoma (pCCA) has largely been defined anatomically, although anatomy alone may not capture oncologic risk. This study evaluated whether biologic burden improves recurrence stratification after curative-intent resection of pCCA.
methodsUsing an international, multi-institutional database, patients undergoing resection without neoadjuvant therapy for non-metastatic pCCA were identified. Literature-based borderline resectability was defined as lymph node metastasis with portal vein/hepatic artery involvement or Bismuth type IV disease. Using a 200-U/mL carbohydrate antigen (CA19-9) cutoff, a three-tier anatomic-biologic borderline resectable (AB-BR) grouping (low, intermediate, high) was derived. The outcome of interest was recurrence-free survival (RFS).
resultsAmong 239 patients (median age, 67.0 years, interquartile range [IQR], 58.0-74.0 years), 38.9% (n = 93) of patients were anatomically borderline resectable (BR). The anatomy-only BR definition did not stratify RFS or overall survival (OS) (both p > 0.05), whereas CA19-9 ≥200 U/mL stratified 2 year RFS within both resectable (55.7% vs. 32.6%) and BR (44.5% vs. 25.3%) groups (all p < 0.05). Four-group analysis demonstrated overlap between resectable/high CA19-9 and BR/low CA19-9, supporting collapsing the categories into AB-BR tiers. The 2 year RFS was 55.7, 37.8, and 25.3% in the low-, intermediate-, and high-risk AB-BR groups, respectively (p = 0.002). The 2 year area under the curve (AUC) value was improved by AB-BR for RFS versus anatomy alone (0.612 vs 0.537). After multivariable adjustment, high-risk AB-BR remained independently associated with higher hazards of recurrence or death (adjusted hazard ratio, 1.86; 95% confidence interval, 1.15-3.00).
conclusionAnatomic BR alone provided limited prognostic stratification. Incorporating CA19-9 improved recurrence prediction and identified an intermediate-risk group not captured by anatomy alone, supporting biologic resectability in pCCA. The AB-BR framework may help move surgical decision-making beyond technical resectability alone toward more oncologically informed treatment selection.
Indexed as
Identifiers
42461558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.